Abstract:Mutations in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD) and are the greatest known genetic risk factors for Parkinson's disease (PD). Communication between the gut and brain and immune dysregulation are increasingly being implicated in neurodegenerative disorders such as PD. Here, we show that flies lacking the Gba1b gene, the main fly orthologue of GBA1 , display widespread NF -k B signalling activation, including gut inflammation, and brain glial activation. We also demonstrate intestinal autophagic defects, gut dysfunction, and microbiome dysbiosis. Remarkably, modulating the microbiome of Gba1b knockout flies, by raising them under germ-free conditions, partially ameliorates lifespan, locomotor and immune phenotypes. Moreover, we show that modulation of the immune deficiency (IMD) pathway is detrimental to the survival of Gba1 deficient flies. We also reveal that direct stimulation of autophagy by rapamycin treatment achieves similar benefits to germ-free conditions independent of gut bacterial load. Consistent with this, we show that pharmacologically blocking autophagosomal-lysosomal fusion, mimicking the autophagy defects of Gba1 depleted cells, is sufficient to stimulate intestinal immune activation. Overall, our data elucidate a mechanism whereby an altered microbiome, coupled with defects in autophagy, drive chronic activation of NF -k B signaling in a Gba1 loss-of-function model. It also highlights that elimination of the microbiota or stimulation of autophagy to remove immune mediators, rather than prolonged immunosuppression, may represent effective therapeutic avenues for GBA1- associated disorders. Alterations in gut microbes are increasingly being linked to neurodegenerative disorders such as Parkinson's disease (PD). Mutations in the GBA1 gene cause Gaucher disease (GD), and are the greatest genetic risk factor for PD. Here we show that Drosophila models lacking the fly orthologue of GBA1 ( Gba1b ) have an altered gut microbiome, which triggers a widespread innate immune response. Accordingly, we show that removal of gut bacteria using antibiotics leads to a reduction in the immune response and health benefits. Stimulating innate immunity, specifically the NF- k B/IMD pathway, shortens the survival of Gba1b deficient flies, suggesting that the overactive immune system is toxic. Conversely, genetic removal of this branch of the immune response is harmful and associated with increased gut bacteria. Lastly, we identify widespread defects in a process called autophagy, which helps degrade and recycle cellular waste. Pharmacologically boosting autophagy extends survival and lowers the gut immune response without changing the gut bacteria. Taken together, our findings suggest that the gut microbiome and autophagy defects in Gba1b deficient flies trigger an abnormal immune response. Thus, drugs which alter the gut microbiome or stimulate autophagy may offer potential therapeutic benefits to patients with GBA1- associated disorders.

Lysosomal storage, impaired autophagy and innate immunity in Gaucher and Parkinson's diseases: insights for drug discovery

Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease

Autophagic dysfunction and gut microbiota dysbiosis cause chronic immune activation in a Drosophila model of Gaucher disease

The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications

Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease

iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis

Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies

The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy

Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology

Glucocerebrosidase and its relevance to Parkinson disease

Common genetic risk for Parkinson's disease and dysfunction of the endo-lysosomal system

Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease

Lipidomic Profiling Reveals Shared and Distinct Pathological Signatures in Sporadic Parkinson's Disease and GBA Mutation Carriers: Implications for Disease Mechanisms

Roles of α‐synuclein in gastrointestinal microbiome dysbiosis‐related Parkinson's disease progression (Review)

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease

Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson’s disease: potential therapeutic targets?

Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy

Glucocerebrosidase as a therapeutic target for Parkinson’s disease

Retromer-dependent lysosomal stress in Parkinson's disease